Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients
| العنوان: | Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients |
|---|---|
| المؤلفون: | Xi Li, Xiao-Ping Chen, Ji-Ye Yin, Xiao-Qing Yuan, Ke-Wei Zhu, Hui Zeng, Xiao-Lin Li, Dao-Yu Zhang, Yong-Long Yang, Yan-Hong Chen, Han Yan |
| المصدر: | Oncotarget |
| بيانات النشر: | Impact Journals LLC, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Pediatrics, law.invention, polymorphism, DNA Methyltransferase 3A, 0302 clinical medicine, AML, law, hemic and lymphatic diseases, Genotype, Antineoplastic Combined Chemotherapy Protocols, DNA (Cytosine-5-)-Methyltransferases, Young adult, Hematology, Clinical pharmacology, Combination chemotherapy, Middle Aged, chemosensitivity, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, embryonic structures, Female, Research Paper, Adult, medicine.medical_specialty, China, Adolescent, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, neoplasms, Survival analysis, Genetic Association Studies, Aged, business.industry, Survival Analysis, 030104 developmental biology, DNMT3A, prognosis, business, Pharmacogenetics |
| الوصف: | // Xiao-Qing Yuan 1, 2 , Dao-Yu Zhang 1, 2 , Han Yan 1, 2 , Yong-Long Yang 3 , Ke-Wei Zhu 1, 2 , Yan-Hong Chen 1, 2 , Xi Li 1, 2 , Ji-Ye Yin 1, 2 , Xiao-Lin Li 4 , Hui Zeng 4 , Xiao-Ping Chen 1, 2, 5 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China 2 Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China 3 Department of Pharmacy, Haikou People’s Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou 570311, P. R. China 4 Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China 5 Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, P. R. China Correspondence to: Xiao-Ping Chen, email: chenxp74@hotmail.com Hui Zeng, email: androps2011@hotmail.com Keywords: DNMT3A, polymorphism, AML, chemosensitivity, prognosis Received: January 15, 2016 Accepted: July 26, 2016 Published: August 09, 2016 ABSTRACT DNMT3A mutation is known as a recurrent event in acute myelogenous leukemia (AML) patients. However, association between DNMT3A genetic polymorphisms and AML patients’ outcomes is unknown. DNMT3A 11 SNPs (rs11695471, rs2289195, rs734693, rs2276598, rs1465825, rs7590760, rs13401241, rs7581217, rs749131, rs41284843 and rs7560488) were genotyped in 344 diagnostic non-FAB-M3 AML patients from southern China. Patients underwent combined chemotherapy with cytarabine and anthracyclines. DNMT3A mRNA expression was analyzed in PBMCs from randomly selected AML patients. Multivariate analysis and combined genotype analysis showed that rs2276598 was associated with increased while rs11695471 and rs734693 were associated with decreased chemosensitivity ( P |
| اللغة: | English |
| تدمد: | 1949-2553 1169-5471 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56365d4c2b25a80f2121d9e8c84ba351Test http://europepmc.org/articles/PMC5312402Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....56365d4c2b25a80f2121d9e8c84ba351 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19492553 11695471 |
|---|